After BioNTech shock: Evotec, Morphosys and Cardiol Therapeutics emerge as the new biotech favorites

Cardiol Therapeutics: First Berlin sees over 200% share price increase potential

Shareholders of Cardiol Therapeutics currently have reason to rejoice. The share price has risen from EUR 0.45 to around EUR 1.00 since April. Nevertheless, the Company is still only valued at around EUR 70 million. The analysts of First Berlin recommend the Cardiol shares as a buy, with a price target of EUR 3.30. Further price increases can now also be contributed by US investors, as the biotech company regained compliance for continuing trading on the Nasdaq. But what makes this Canadian company so interesting?

Cardiol Therapeutics is focused on diseases of the cardiovascular system. Research is being conducted into anti-inflammatory and anti-fibrotic therapies. The most advanced is the development of CardiolRx™. It is intended to be used as an oral solution for the treatment of debilitating forms of inflammatory heart disease that affect a younger age demographic, and where treatment is not addressed adequately by currently available therapies. The effectiveness of CardiolRx™ is currently being investigated in a Phase II study in the US involving 25 patients with recurrent pericarditis and an international Phase II study involving 100 patients with acute myocarditis. Results for both studies are anticipated in the coming year. Analysts from First Berlin estimate Cardiol's annual revenue potential from these two indications to be around USD 1.5 billion. Cardiol is also in a solid financial position with cash and cash equivalents sufficient to finance research until 2026. Therefore, the Company is considered "significantly undervalued."

Evotec: Buy after the profit warning?

In contrast, Evotec already weighs in at almost EUR 4 billion. This biotech share has also developed positively in recent months and is now trading at around EUR 22. At the end of April, it was only EUR 16.60. Even a hacker attack and an earnings warning did little to harm the share. Management emphasized that it is on track to achieve its medium-term targets by 2025. Optimization measures are also expected to contribute to this. For example, costs of up to EUR 25 million are to be saved. Analysts, for the most part, remained unfazed by the profit warning. Among the optimists is Warburg, with a price target of EUR 30. For the analysts, the slight price slide offers an opportunity to enter. For Deutsche Bank, the Evotec share is a hold. The analysts reduced sales and earnings expectations after the hacker attack. Their price target is EUR 20, around 10% below the current price.

Morphosys: Important study results expected at year-end

Things are getting exciting at Morphosys today. The Company is releasing its numbers for the second quarter and the first half of the year. Additionally, a conference call is scheduled for tomorrow. After the significant rise in the share price in recent months, expectations are likely to be high. After all, the share has almost doubled since the beginning of April to EUR 27.

Analyst opinions vary widely when it comes to the question of how the share will fare. According to UBS, there is still a lot more potential. The analysts take a positive view of the Morphosys hopeful Pelabresib. There should be new study results on Pelabresib later in the year. The analysts' price target is EUR 47. Accordingly, they recommend the share as a "buy". In contrast, Goldman Sachs rates the Morphosys share as "Sell". In order to reach the analysts' price target of EUR 12.50, the share would have to more than halve in value. The analysts do not expect any new impetus from the quarterly figures, as the important study data will still take several months to emerge. Morphosys currently has a market capitalization of almost EUR 1 billion.

Investors appear to be returning to biotech stocks, although certainly not to all of them. BioNTech is currently clearly on the sidelines. In contrast, the charts of Cardiol Therapeutics, Evotec and Morphosys show positive momentum. Due to the low valuation and high cash position, analysts see the greatest upside potential in Cardiol.